Browsing Tag
Melbourne
67 posts
NRW Holdings wins A$115m first stage of A$300m Melbourne data centre package
NRW Holdings Limited subsidiary Fredon has secured an initial A$115 million mechanical package for STACK Infrastructure’s 864MW MEL03 hyperscale campus, deepening the contractor’s exposure to Australia’s artificial intelligence-driven data centre buildout.
Adore Beauty revenue hit A$207.3m but EBITDA fell 39%. Why is Kylie Archer staying as CFO?
Adore Beauty Group has permanently appointed former Nick Scali finance chief Kylie Archer as CFO after record revenue collided with weaker earnings during the Australian beauty retailer’s costly expansion into physical stores.
SKS Technologies (ASX: SKS) targets A$500m revenue as data centres become nearly 87% of its pipeline
SKS Technologies targets A$500m FY27 revenue after NPAT jumped 93%, with data centres now driving 60% of sales and 87% of its A$1.69bn pipeline.
Reliance Worldwide gets A$4.75 Brookfield bid as 95% statutory profit fall puts recovery value in play
Brookfield offers A$4.75 a share for Reliance Worldwide as FY26 profit drops 95%, putting takeover terms and ASX's FY27 margin recovery firmly in focus.
4DMedical (ASX: 4DX) jumps 13% as SimonMed rollout nears
4DMedical has record scans and A$278m cash, but its A$2.2bn value now depends on turning SimonMed’s US network into paid CT:VQ revenue.
Qualitas lifts AI-backed margin target above 60% as ASX:QAL recovery accelerates
Qualitas Limited is moving artificial intelligence from employee productivity tools into core credit underwriting, targeting a higher-margin funds management platform without proportionately increasing headcount.
Avecho Biotechnology clears Phase III insomnia interim review as ASX:AVE surges 40%
Avecho Biotechnology’s CBD insomnia trial will continue with its original 519-patient design after an independent monitoring board found that predefined efficacy and safety requirements had been satisfied.
Alterity Therapeutics (ASX:ATH) has FDA clarity, but Phase 3 funding now tests the rally
Alterity has FDA clarity for ATH434. The bigger question is whether ASX:ATH can fund and execute Phase 3 without losing momentum.
Synertec (ASX: SOP) drops as Hitachi Energy collaboration excitement fades into post-update profit-taking
Synertec just signed Hitachi Energy. The Powerhouse is AI-powered grid tech. The market cap is A$12m. The analyst consensus target is 400% above current.
Tabcorp (ASX: TAH) collapse deepens as AUSTRAC compliance probe revives 2017 AML breach memories
Tabcorp paid A$45m for AML breaches in 2017. AUSTRAC just sent another letter. The market priced in the worst case before management could speak.